Laverock Therapeutics Raises £13.5M for Gene Silencing Platform
Laverock Therapeutics, a Stevenage, UK-based provider of a gene silencing platform, recently announced that it has raised £13.5M in Seed funding. The funding round was led by Calculus Capital, with participation from Eli Lilly and Company, Mercia Ventures, Maven Capital Partners, Eos, UK Innovation & Science Seed Fund, and Tekfen Ventures. This significant investment will allow Laverock Therapeutics to further develop its gene silencing platform, known as GEiGS, and advance its therapeutic applications in regenerative medicine and immuno-oncology.
Established in 2021, Laverock Therapeutics is led by CEO David Venables and is focused on creating programmable advanced human therapeutic applications through its gene silencing platform.
GEiGS stands out from other gene silencing approaches due to its core stable, tunable, and programmable attributes, which ensure cell type- or condition-specific activity. The platform uses universal gene editing tools to minimally edit non-coding genes and redirect their silencing activity (RNAi) towards a new target gene.
The funding received will be utilized to further advance the development of Laverock Therapeutics' GEiGS technology and progress its programs in regenerative medicine and immuno-oncology. The company will particularly focus on Type I Diabetes and solid tumor-responsive T-cell and macrophage-based immune therapies, conducting in vitro and in vivo validation. Additionally, Laverock Therapeutics plans to expand its team by bringing on new members and enhancing its lab facilities to support its next phase of growth.
They've invested in Laverock Therapeutics
Get to know these Biotech investors
Click here for a full list of 6,481+ startup investors in the UK